Persistent hematuria was predictive of adverse outcomes among patients with LN, regardless of achieving clinical remission.

Akebia Therapeutics is refocusing on Vafseo for dialysis patients, discontinuing expansion to non-dialysis, which has reset ...

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in ...

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

Objectives The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for ...

Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs ...

Low proteinuria does not indicate better kidney outcomes or treatment response in patients with lupus nephritis; ...

The optimal hydroxychloroquine blood level in lupus is between 750 ng/mL and 1,150 ng/mL, which can help prevent active ...

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

In a new study, researchers have discovered a connection between inflammation in the areas of interstitial fibrosis and tubular atrophy (IFTA), a common pattern of kidney damage often seen in kidney ...

Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately ...